Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier

American Journal of Pathology

Volumn 180, Issue 2, 2012, Pages 672-681

  Copland, David A ^a   Liu, Jian ^a   Schewitz Bowers, Lauren P ^a   Brinkmann, Volker ^b   Anderson, Karen ^c   Nicholson, Lindsay B ^a   Dick, Andrew D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD EYE BARRIER; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; EYE INFLAMMATION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; RETINA CELL; SINGLE DRUG DOSE; UVEORETINITIS;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; BLOOD-RETINAL BARRIER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICROVESSELS; PERMEABILITY; PROPYLENE GLYCOLS; RETINITIS; SPHINGOSINE; UVEITIS;

EID: 84856020532     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.10.008     Document Type: Article

References (55)

1. A.D. Dick Immune mechanisms of uveitis: insights into disease pathogenesis and treatment Int Ophthalmol Clin 40 2000 1 18
2. R.R. Caspi Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens Immunol Res 27 2003 149 160
3. D.C. Gritz, I.G. Wong Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study Ophthalmology 111 2004 491 500 discussion 500
4. G.J. Williams, S. Brannan, J.V. Forrester, M.P. Gavin, S.P. Paterson-Brown, A.T. Purdie, M. Virdi, J.A. Olson The prevalence of sight-threatening uveitis in Scotland Br J Ophthalmol 91 2007 33 36
5. A. Rothova, M.S. Suttorp-van Schulten, W. Frits Treffers, A. Kijlstra Causes and frequency of blindness in patients with intraocular inflammatory disease Br J Ophthalmol 80 1996 332 336
6. A.D. Dick Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol 79 1995 81 88
7. J.V. Forrester, J. Liversidge, H.S. Dua, H. Towler, P.G. McMenamin Comparison of clinical and experimental uveitis Curr Eye Res 9 Suppl 1990 75 84
8. W.B. Wacker Retinal autoimmunity: two decades of research Jpn J Ophthalmol 31 1987 188 196
9. W.B. Wacker Proctor Lecture Experimental allergic uveitis. Investigations of retinal autoimmunity and the immunopathologic responses evoked Invest Ophthalmol Vis Sci 32 1991 3119 3128
10. L. Atalla, M. Linker-Israeli, L. Steinman, N.A. Rao Inhibition of autoimmune uveitis by anti-CD4 antibody Invest Ophthalmol Vis Sci 31 1990 1264 1270
11. R.R. Caspi Immunogenetic aspects of clinical and experimental uveitis Reg Immunol 4 1992 321 330
12. S.R. Thurau, C.C. Chan, R.B. Nussenblatt, R.R. Caspi Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals Clin Exp Immunol 109 1997 370 376
13. S. Hoey, P.S. Grabowski, S.H. Ralston, J.V. Forrester, J. Liversidge Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism J Immunol 159 1997 5132 5142
14. D.A. Copland, M.S. Wertheim, W.J. Armitage, L.B. Nicholson, B.J. Raveney, A.D. Dick The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation Invest Ophthalmol Vis Sci 49 2008 5458 5465
15. E.C. Kerr, B.J. Raveney, D.A. Copland, A.D. Dick, L.B. Nicholson Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations J Autoimmun 31 2008 354 361
16. H. Xu, J.V. Forrester, J. Liversidge, I.J. Crane Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules Invest Ophthalmol Vis Sci 44 2003 226 234
17. F.R. Imrie, A.D. Dick Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis Curr Opin Ophthalmol 18 2007 212 219
18. M. Fujino, N. Funeshima, Y. Kitazawa, H. Kimura, H. Amemiya, S. Suzuki, X.K. Li Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment J Pharmacol Exp Ther 305 2003 70 77
19. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel-Wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, L. Kappos TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
20. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L. Zhang-Auberson, P. Burtin FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
21. J.A. Cohen, J. Chun Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis Ann Neurol 69 2011 759 777
22. K. Chiba FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors Pharmacol Ther 108 2005 308 319
23. K. Chiba, Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi, M. Ohtsuki, Y. Hoshino FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing J Immunol 160 1998 5037 5044
24. Y. Yanagawa, K. Sugahara, H. Kataoka, T. Kawaguchi, Y. Masubuchi, K. Chiba FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo J Immunol 160 1998 5493 5499
25. V. Brinkmann, M.D. Davis, C.E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, C.A. Foster, M. Zollinger, K.R. Lynch The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 2002 21453 21457
26. S. Mandala, R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G.J. Shei, D. Card, C. Keohane, M. Rosenbach, J. Hale, C.L. Lynch, K. Rupprecht, W. Parsons, H. Rosen Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 296 2002 346 349
27. M. Matloubian, C.G. Lo, G. Cinamon, M.J. Lesneski, Y. Xu, V. Brinkmann, M.L. Allende, R.L. Proia, J.G. Cyster Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 2004 355 360
28. V. Brinkmann Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology Pharmacol Ther 115 2007 84 105
29. S.R. Schwab, J.G. Cyster Finding a way out: lymphocyte egress from lymphoid organs Nat Immunol 8 2007 1295 1301
30. S. Kurose, E. Ikeda, M. Tokiwa, N. Hikita, M. Mochizuki Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats Exp Eye Res 70 2000 7 15
31. A.G. Commodaro, J.P. Peron, C.T. Lopes, C. Arslanian, R. Belfort Jr, L.V. Rizzo, V. Bueno Evaluation of experimental autoimmune uveitis in mice treated with FTY720 Invest Ophthalmol Vis Sci 51 2010 2568 2574
32. B.J. Raveney, D.A. Copland, L.B. Nicholson, A.D. Dick Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease Arch Ophthalmol 126 2008 1390 1395
33. M. Paques, J.L. Guyomard, M. Simonutti, M.J. Roux, S. Picaud, J.F. Legargasson, J.A. Sahel Panretinal, high-resolution color photography of the mouse fundus Invest Ophthalmol Vis Sci 48 2007 2769 2774
34. H. Xu, P. Koch, M. Chen, A. Lau, D.M. Reid, J.V. Forrester A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images Exp Eye Res 87 2008 319 326
35. S. Thangada, K.M. Khanna, V.A. Blaho, M.L. Oo, D.S. Im, C. Guo, L. Lefrancois, T. Hla Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics J Exp Med 207 2010 1475 1483
36. W. Collins, J. Cohen, P. O'Connor, A. de Vera, L. Zhang-Auberson, F.J. Jin, L. Kappos Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies (abstract) Mult Scler 16 10 suppl 2010 S295 Abstracts. Mult Scler 2010, 16(10 Suppl):S7S352
37. R.R. Caspi, C.C. Chan, Y. Fujino, F. Najafian, S. Grover, C.T. Hansen, R.L. Wilder Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis J Neuroimmunol 47 1993 177 188
38. C.J. Calder, L.B. Nicholson, A.D. Dick A selective role for the TNF p55 receptor in autocrine signaling following IFN-gamma stimulation in experimental autoimmune uveoretinitis J Immunol 175 2005 6286 6293
39. M.J. Robertson, L.P. Erwig, J. Liversidge, J.V. Forrester, A.J. Rees, A.D. Dick Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis Invest Ophthalmol Vis Sci 43 2002 2250 2257
40. R.R. Caspi Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis Int Rev Immunol 21 2002 197 208
41. D. Luger, P.B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E.P. Bowman, N.M. Sgambellone, C.C. Chan, R.R. Caspi Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category J Exp Med 205 2008 799 810
42. B.J. Raveney, D.A. Copland, A.D. Dick, L.B. Nicholson TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis J Immunol 183 4 2009 2321 2329
43. C.A. Foster, L.M. Howard, A. Schweitzer, E. Persohn, P.C. Hiestand, B. Balatoni, R. Reuschel, C. Beerli, M. Schwartz, A. Billich Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis J Pharmacol Exp Ther 323 2007 469 475
44. J.E. Hughes, S. Srinivasan, K.R. Lynch, R.L. Proia, P. Ferdek, C.C. Hedrick Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages Circ Res 102 2008 950 958
45. B.A. Durafourt, C. Lambert, T.A. Johnson, M. Blain, A. Bar-Or, J.P. Antel Differential responses of human microglia and blood-derived myeloid cells to FTY720 J Neuroimmunol 230 2011 10 16
46. D.A. Copland, C.J. Calder, B.J. Raveney, L.B. Nicholson, J. Phillips, H. Cherwinski, M. Jenmalm, J.D. Sedgwick, A.D. Dick Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis Am J Pathol 171 2007 580 588
47. M. Mehling, T.A. Johnson, J. Antel, L. Kappos, A. Bar-Or Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis Neurology 76 2011 S20 S27
48. T.A. Johnson, B.L. Evans, B.A. Durafourt, M. Blain, Y. Lapierre, A. Bar-Or, J.P. Antel Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients J Immunol 187 2011 570 579
49. M.L. Oo, S. Thangada, M.T. Wu, C.H. Liu, T.L. Macdonald, K.R. Lynch, C.Y. Lin, T. Hla Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor J Biol Chem 282 2007 9082 9089
50. P. Bandhuvula, Y.Y. Tam, B. Oskouian, J.D. Saba The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity J Biol Chem 280 2005 33697 33700
51. M.L. Oo, S.H. Chang, S. Thangada, M.T. Wu, K. Rezaul, V. Blaho, S.I. Hwang, D.K. Han, T. Hla Engagement of S1P1-degradative mechanisms leads to vascular leak in mice J Clin Invest 121 2011 2290 2300
52. T. Sanchez, T. Estrada-Hernandez, J.H. Paik, M.T. Wu, K. Venkataraman, V. Brinkmann, K. Claffey, T. Hla Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability J Biol Chem 278 2003 47281 47290
53. E. Camerer, J.B. Regard, I. Cornelissen, Y. Srinivasan, D.N. Duong, D. Palmer, T.H. Pham, J.S. Wong, R. Pappu, S.R. Coughlin Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice J Clin Invest 119 2009 1871 1879
54. H. Xu, R. Dawson, I.J. Crane, J. Liversidge Leukocyte diapedesis in vivo induces transient loss of tight junction protein at the blood-retina barrier Invest Ophthalmol Vis Sci 46 2005 2487 2494
55. A.P. Cope, R.S. Liblau, X.D. Yang, M. Congia, C. Laudanna, R.D. Schreiber, L. Probert, G. Kollias, H.O. McDevitt Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling J Exp Med 185 1997 1573 1584